Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of Relatlimab Alone and in Combination with Nivolumab in Advanced Solid Tumors (Japan)
jRCT2080223428Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jan 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of relatlimab and nivolumab in Nonhematologic neoplasms and solid tumor (2 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Safety and tolerability of relatlimab alone and in combination with nivolumab and Preliminary antitumor efficacy of relatlimab alone and in combination with nivolumab. Started Jan 2017; status: completed.
02
Drugs
relatlimabnivolumab
03
Conditions
Nonhematologic neoplasmssolid tumor
Beyond the preview
Go deeper on jRCT2080223428.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223428.